Electra Therapeutics prices $350 million upsized IPO at $15 per share
Electra Therapeutics priced its IPO at $15 per share, raising $350 million. The biopharmaceutical company sold 23.3 million shares, with an option for 3.5 million more. Shares will trade on Nasdaq under the ticker ETRA. The funds will support its pipeline for immune-mediated diseases and cancer.
How this was made
The 30-second read
Why it matters
The $350 M raise funds its registrational program for sHLH and other immune disorders, positioning the company for upcoming trial readouts and potential partnerships.
Market read
The IPO adds liquidity to the biotech sector and provides a new vehicle for investors seeking exposure to immune‑mediated disease therapies.
What to watch
Potential dilution from the over‑allotment option and future financing needs if trials miss milestones.
Background
Electra Therapeutics is a late‑stage biopharma focused on immune‑mediated diseases and cancer, entering public markets for the first time.
Ticker impact
Electra Therapeutics priced its IPO at $15, raising $350 million, initiating trading on Nasdaq.
Opening price likely to trade near $15 with modest upside as demand was strong.
First‑day pricing and over‑allotment option signal strong investor appetite; biotech IPOs of this size often see initial price stability or modest gain.
Market effects
Adds a new listed biotech to the sector, may lift peer valuations in late‑stage immunology space.
Boosts Nasdaq biotech listings and may attract further capital to US biotech IPO pipeline.
Highlights continued investor appetite for high‑risk, high‑reward biotech offerings worldwide.
Counterpoint
If clinical data for ipsoprubart falters, the IPO could face rapid devaluation despite strong start.
Key entities
- UnderwriterJefferies
Joint book‑running manager for the IPO.
- UnderwriterTD Cowen
Joint book‑running manager for the IPO.
- UnderwriterEvercore ISI
Joint book‑running manager for the IPO.
- UnderwriterCantor
Joint book‑running manager for the IPO.
